Product Pipeline Neratinib across the breast cancer therapy spectrum

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advances and Emerging Therapy for Lung Cancer

Integration of Taxanes in the Management of Breast Cancer

Xeloda X-panding options in the adjuvant treatment of breast cancer

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

Open Clinical Trials: What’s Out There Now Paula D. Ryan, MD, PhD

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Drug Treatment of Metastatic Breast Cancer

Shanghai, China March 24 th 2001 Xeloda Future Developments Mr. John Collins.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

¿Qué ver en ASCO 2017?.

Volume 97, Pages (December 2016)

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Intention-to-treat population

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

Managing Metastatic Bone Pain: The Role of Bisphosphonates

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Product Pipeline Neratinib across the breast cancer therapy spectrum

Metastatic HER2+ Breast Cancer: Resistance

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

New Horizons in the Management of Advanced Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Her2-positive breast cancer: updating current best practice

سرطان الثدي Breast Cancer

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

HER2+ breast cancer: from RCT to the real world scenario

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

CDK4/6 Inhibitors in Breast Cancer:

Krop I et al. SABCS 2009;Abstract 5090.

Managing gBRCA-Positive Metastatic Breast Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Treatment of HR+ Breast Cancer: A Clinical Update

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Baselga J et al. SABCS 2009;Abstract 45.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Product Pipeline Neratinib across the breast cancer therapy spectrum

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Clinical Focus.

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Product Pipeline Neratinib across the breast cancer therapy spectrum Phase I Phase II Phase III Registration Approval HER2+ Breast Cancer Extended adjuvant Neratinib monotherapy Metastatic Monotherapy or combination therapy Metastatic w/ brain mets Neoadjuvant Combination with standard therapy HER2-mutant Breast Cancer/Solid Tumors Neratinib (± fulvestrant in MBC) NDA filed 07/16 MAA filed 06/16 EAP/MAP CONTROL ExteNET (Phase III HER2+ EBC) NALA (Phase III 3rd Line HER2+ MBC) FB-10: T-DM1 + neratinib NEfERTT (Phase II HER2+MBC) NSABP FB-7 TBCRC-022 I-SPY 2 NSABP FB-7 SUMMIT (Basket Trial) Phase II trial (WashU) Copyright 2017 Puma Biotechnology